Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Canada / NCT05157932
Active, not recruiting Not applicable

An Evaluation of the Talk Test for Exercise Prescription for Home-Based Cardiac Rehabilitation

NCT05157932 · tracked via the Priya Life Science Canada tracker
Phase
Not applicable
Started
2022-07-08
Last updated
2026-07-02

Condition(s) studied

Coronary Artery Disease

Investigational drug(s) / intervention(s)

Talk test prescriptionCPET prescription

Talk test prescription: Participants will be enrolled in the virtual cardiac rehab program and receive an exercise prescription based on the Talk test method.

CPET prescription: Participants will be enrolled in the virtual cardiac rehab program and receive an exercise prescription based on their CPET results completed at baseline

Study summary

The objectives of this pilot RCT are to examine if the Talk Test is an effective and safe tool as compared with CPET for exercise prescription in patients who have undergone CABG or PCI and enrolled in a home-based CR program with virtual exercise training monitoring.

Eligibility

Sex
ALL
Min age
40 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * recently underwent PCI or CABG (at least 4 weeks but less than 12 weeks post-event or procedure); * able to perform a CPET; * at least 40 years of age; * access to MyChart; and, * access to email and the internet * access to a cellphone with broadband internet (4G, LTE, 5G). Exclusion Criteria: * currently participating in a virtual or on-site CR program; * ventricular ejection fraction ≤45%; * unstable angina or established diagnosis of chronic obstructive pulmonary disease, severe mitral or aortic stenosis, or hypertrophic obstructive cardiomyopathy; * unable to return for 12-week follow-up visits.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
University of Ottawa Heart Institute Ottawa Ontario

More Ottawa Heart Institute Research Corporation trials in Canada

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05157932 on ClinicalTrials.gov ↗ ← All trials in Canada